Introduction
• Vasoactive drugs (VaD) are commonly used to correct abnormal haemodynamics of organ donors in Intensive Care Units (ICU).
• VaDs can differentially affect insulin secretion positively (dobutamine) or negatively (noradrenaline).
Aim
• We hypothesised that some VaDs might induce beta-cell stress/death and be associated with adverse pancreas transplant outcomes.
• We aimed to assess relationships of VaD use to pancreas transplant graft survival.
Methods

Results
• We used Cox-regression in UK Transplant registry data (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) to assess associations between use of five VaDs and covariate-adjusted pancreas graft survival (median follow-up: 3 years) before and after correction for multiple testing (p-value threshold: <0.01).
Conclusions
• Noradrenaline use was associated with better graft survival in models adjusting for donor and recipient variables but not after correcting for multiple testing.
• Further research is required to replicate these findings and establish whether relationships are truly significant and causal before any change in practice is made.
• Better outcomes associated with noradrenaline use could be explained by inhibition of pancreatic insulin secretion thereby resting beta-cells at a time of high metabolic stress. Noradrenaline use vs non-use • Use of adrenaline, dopamine and vasopressin were not related to graft survival.
